A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of RA101495 in Subjects With Generalized Myasthenia Gravis

Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of RA101495 in Subjects With Generalized Myasthenia Gravis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Apr 2018

At a glance

  • Drugs RA 101495 (Primary)
  • Indications Myasthenia gravis
  • Focus Therapeutic Use
  • Sponsors Ra Pharmaceuticals
  • Most Recent Events

    • 01 Mar 2018 Design of this trial will be presented at the 70th Annual American Academy of Neurology (AAN) Meeting 2018, according to a Ra Pharmaceuticals media release.
    • 21 Dec 2017 According to a Ra Pharmaceuticals media release, all patients will have the opportunity to receive RA101495 SC in a long-term extension study.
    • 21 Dec 2017 According to a Ra Pharmaceuticals media release, the company has initiated dosing in the trial and topline data is expected in the first half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top